🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

RecruitingNAAges 18 Years - anyAllBeijing Chao Yang Hospital
NCT06676085 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * age older than 18 years old * received VV ECMO because of severe respiratory failure Exclusion Criteria: * anticoagulant contraindications * cerebral infarction or suspected patients * severe hypertension * women in gestational and lactational period * hemophilia * allergic to heparin or Nafamostat * unwilling or unable to complete the study
💊

What it tests

  • Nafamostat
  • Heparin
📍

Where

1 site
Bing Sun
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy